Equities

Ginwa Enterprise Group Inc

600080:SHH

Ginwa Enterprise Group Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)5.72
  • Today's Change-0.06 / -1.04%
  • Shares traded1.15m
  • 1 Year change-22.49%
  • Beta0.8909
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments676578648
Total Receivables, Net142317137
Total Inventory262535
Prepaid expenses232730
Other current assets, total3341.862.53
Total current assets1,201949853
Property, plant & equipment, net273547537
Goodwill, net------
Intangibles, net868888
Long term investments507349362
Note receivable - long term------
Other long term assets------
Total assets2,1091,9741,870
LIABILITIES
Accounts payable9.281616
Accrued expenses111714
Notes payable/short-term debt726741
Current portion long-term debt/capital leases5.354.15--
Other current liabilities, total35016979
Total current liabilities447273150
Total long term debt5.43120
Total debt838341
Deferred income tax1.956.174.97
Minority interest--00
Other liabilities, total160.2659
Total liabilities470291214
SHAREHOLDERS EQUITY
Common stock373373373
Additional paid-in capital821821821
Retained earnings (accumulated deficit)569605572
Treasury stock - common------
Unrealized gain (loss)(126)(116)(110)
Other equity, total------
Total equity1,6381,6841,656
Total liabilities & shareholders' equity2,1091,9741,870
Total common shares outstanding373373373
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.